Cancer Research and Treatment (Cancer Res
Treat) is a peer-reviewed publication of the Korean Cancer Association.
Cancer Research and Treatment is published quarterly on the last day
of March, June, September, and December, one volume per year. Cancer
Research and Treatment accepts manuscripts for submission under a broad
scope of topics relevant to experimental and clinical cancer research.
Subjects include carcinogenesis, tumor biology, molecular oncology,
cancer genetics, tumor immunology, epidemiology, predictive markers
and cancer prevention, pathology, cancer diagnosis, screening, and therapies
including chemotherapy, surgery, radiation therapy, immunotherapy, gene
therapy, multimodality treatment, and palliative care. Physicians or
researchers throughout the world can submit a manuscript if its scope
is appropriate. Manuscripts should be submitted in English.
Manuscripts for submission to Cancer Research and Treatment should be
prepared according to the following instructions. Cancer Research and
Treatment follows the Uniform Requirements for Manuscripts Submitted
to Biomedical Journals: Writing and Editing for Biomedical Publication
(http://www.icmje.org/urm_main.html),
commonly known as "Vancouver style" if not otherwise described
below.
1. RESEARCH AND PUBLICATION ETHICS
The journal adheres to the ethical guidelines for research
and publication described in Good Publication Practice Guidelines
for Medical Journals (http://kamje.or.kr/publishing_ethics.html)
and Guidelines on Good Publication (http://www.publicationethics.org.uk/guidelines).
Registration of Clinical Trial Research
It is recommended that any research dealing with a clinical trial be
registered with a primary national clinical trial registration site
such as http://ncrc.cdc.go.kr/cris,
or other sites accredited by the WHO or the International Committee
of Medical Journal Editors.
Conflict-of-Interest Statement
The corresponding author must inform the editor of any potential conflicts
of interest that could influence the authors' interpretation of the
data. Examples of potential conflicts of interest are financial support
from or connections to pharmaceutical companies, political pressure
from interest groups, and academically related issues. In particular,
all sources of funding applicable to the study should be explicitly
stated.
Statement of Informed Consent
Copies of written informed consent and Institutional Review Board (IRB)
approval for clinical research should be kept. If necessary, the editor or
reviewers may request copies of these documents to resolve questions
about IRB approval or study conduct.
Statement of Human and Animal Rights
All human investigations must be conducted according to the principles
expressed in the Declaration of Helsinki. All studies involving animals must
state that the guidelines for the use and care of laboratory animals of the
authors' institution, or any national law, were followed.
Authorship
Authorship credit should be based on 1) substantial contributions to
conception and design, acquisition of data, or analysis and interpretation of
data; 2) drafting the article or revising it critically for important intellectual
content; and 3) final approval of the version to be published. Each author
should meet these 3 conditions. If the number of authors is greater than six,
there should be a list of each author's role for the submitted paper.
Originality and Duplicate Publication
All submitted manuscripts should be original and should not be considered
by other scientific journals for publication at the same time. No part of the
accepted manuscript should be duplicated in any other scientific journal
without the permission of the Editorial Board. If duplicate publication related
to the papers of this journal is detected, the authors will be announced in
the journal and their institutes will be informed, and there will also be
penalties for the authors.
Secondary Publication
It is possible to republish manuscripts if the manuscripts satisfy the
conditions of secondary publication of the Uniform Requirements
for Manuscripts Submitted to Biomedical Journals.
2. MANUSCRIPT CATEGORIES
Original Articles
Original Articles are the primary presentation mode of scientific
communication in the journal. Original Articles are generally reviewed at
least by two peer reviewers and, when required, a biostatistician.
Comments offered by reviewers are returned to the authors for their
consideration. Acceptance of manuscripts is based on many factors,
including the importance of the research to the field of oncology and the
originality of the work. Authors are encouraged to focus on accuracy, clarity,
and brevity in their presentations.
Review Articles
Review Articles are usually solicited by the Editor-in-Chief. However,
unsolicited Reviews will also be considered, in which case authors should
contact the Editor-in-Chief in advance to determine the appropriateness
of the Review to the journal. Please send an e-mail to Il Han Kim, Editor-in-
Chief, at
Editorials
Editorials are usually solicited by the Editor-in-Chief to accompany a
published article or an accepted manuscript. Editorials should be no more
than four to five pages in length.
Special Articles
Special Articles include those manuscripts for which content and style
do not fall under the category of Original Articles or Review Articles;
these may include, but are not limited to, guidelines, summaries of
consensus meetings, and other scholarly communications. Submissions
should be prepared according to the "Manuscript Preparation Guidelines."
Case Reports
Case Reports are not encouraged and consider only if justified by their
unique significance. Case Reports with visual images, in color or black
and white, including x-rays or scans of characteristic or classic conditions
relevant to oncology, are invited for consideration. Each submission
should be accompanied by a brief overview describing the topic, and
figure descriptions should be included within the case report.
Letters to the Editor
The Editors welcome readers' comments on articles published recently in
the journal or topics of interest.
3. PEER REVIEW PROCESS
The acceptance criteria for all papers are based on the
quality and originality of the research and its clinical and scientific
significance. Original Articles are generally reviewed by at least two
peer reviewers and, when required, a biostatistician. An initial decision
will normally be made within 4 weeks of receipt of a manuscript, and
the reviewers' comments are sent to the corresponding authors by e-mail.
Revised manuscripts must be submitted online by the corresponding author.
The corresponding author must indicate the alterations that have been
made in response to the referees' comments item by item. Failure to
resubmit the revised manuscript within 12 weeks of the editorial decision
is regarded as a withdrawal.
4. ELECTRONIC SUBMISSION
OF A MANUSCRIPT
Manuscripts are submitted online to Cancer Research and Treatment via
Homepage (http://journal.cancer.or.kr).
Submission instructions are available at the website. All articles submitted
to the journal must comply with these instructions. Failure to do so
will result in return of the manuscript and a possible delay in publication.
For assistance please contact us via e-mail (),
telephone (+), or fax (+).
5. MANUSCRIPT PREPARATION
General Guidelines
Manuscripts must be written succinctly in clear, grammatical English. All
manuscripts originating from non-English speaking countries must be revised by a professional linguistic reviewer, and it must be evident from the
cover letter that this has been done. All manuscripts are subject to editorial
peer review. The editors reserve the right to improve the style and, if
necessary, return the manuscript to the author for revision. When a
manuscript is received for consideration, the editors assume that no similar
paper has been or will be submitted for publication elsewhere. The main
document with manuscript text and tables should be prepared with MS
Word or HWP files.
| |
• |
The manuscript should be written in 10-point font
with double-line spacing on A4 sized (21.0×29.7 cm) paper with 2.5
cm margins on the top, bottom, right, and left. |
| |
• |
All manuscript pages are to be consecutively numbered at the middle
of the bottom, beginning with the title page as page 1. |
| |
• |
The use of acronyms and abbreviations is discouraged and should
be kept to a minimum. When used, they are to be defined where first
used, followed by the acronym or abbreviation in parentheses. |
| |
• |
Drug and chemical names should be stated in standard chemical
or generic nomenclature. Units of measure should be presented according
to the International System (SI) of units. |
| |
|
|
Reporting Guidelines for Specific Study Designs
For the specific study design, such as randomized control studies, studies
of diagnostic accuracy, meta-analyses, observational studies and nonrandomized
studies, it is recommended that the authors follow the reporting guidelines
listed in the following Table.
Initiative |
Type
of study |
Source |
CONSORT |
Randomized controlled trials |
http://www.consort-statement.org/ |
STARD |
Studies of
diagnostic accuracy |
http://www.stard-statement.org/ |
PRISMA |
Preferred reporting items of
systematic |
http://www.prisma-statement.org/ |
STOBE |
Observational
studies in epidemiology |
http://www.strobe-statement.org/ |
| MOOSE |
Meta-analyses
of observational studies in epidemiology |
http://www.consort-statement.org/resources/downloads/other-instruments/moose-statement-2000.pdf |
ORIGINAL ARTICLES
Original articles are reports of basic or clinical investigations. Although there
is no limitation on the length of these manuscripts, the Editorial Board may
abridge excessive illustrations and large tables. The manuscript for an
original article should be organized on a separate page in the following
sequence: title page, abstract and keywords, text, conflicts of interest,
acknowledgments (if necessary), references, tables, and figure legends.
| 1) Title page: |
| |
The Title Page should carry
the following information. |
| |
• |
Manuscript title, which should be concise
but informative. |
| |
• |
Each author's name (given name, middle name, and surname)
followed by the highest academic degree. |
| |
• |
The name of the department(s) and institution(s) where
the work was conducted |
| |
• |
A running title of fewer than 50 characters. |
| |
• |
The complete mailing address, telephone, facsimile,
and e-mail address for correspondence and reprints. |
| |
|
|
| 2) Abstract and Keywords: |
| |
The abstract should be no
more than 250 words, and describe concisely, in a paragraph, the
Purpose(s), Materials and Methods, Results, and Conclusion(s). Below
the abstract, authors should provide 3 to 10 keywords or terms to
be used as index terms. Terms from the Medical Subject Headings
(MeSH) list (http://www.nlm.nih.gov/mesh/MBrowser.html)
should be used; if suitable MeSH terms are not yet available for
recently introduced terms, current terms may be used. |
| |
|
|
| |
3) Text: |
| |
The text should be arranged
in this order: Introduction, Materials & Methods, Results, Discussion,
Conclusion(s). Footnotes are to be used only for tables and figures.
Identify precisely all drugs and chemicals used, including generic
name(s), dose(s), route(s) of administration, and city and country
of manufacturer. Use only standard abbreviations. A subject that
is to be abbreviated must be spelled in full for its first use in
the text, followed by the abbreviation in parentheses. |
| |
|
|
| |
4) Conflicts of Interest: |
| |
All potential conflicts of
interest must be stated within the text of the manuscript, under
this heading. This pertains to relationships with pharmaceutical
companies, biomedical device manufacturers, or other corporations
whose products or services are related to the subject matter of
the article. Such relationships include, but are not limited to,
employment by a industrial concern, ownership of stock, membership
on a standing advisory council or committee, being on the board
of directors, or being publicly associated with the company or its
products. Other areas of real or perceived conflict of interest
could include receiving honoraria or consulting fees or receiving
grants or funds from such corporations or individuals representing
such corporations. Please state "None" if no conflicts
exist. |
| |
|
|
| |
5) Acknowledgments: |
| |
If necessary, persons who
have made substantial contributions, but who have not met the criteria
for authorship, are acknowledged here. All sources of funding applicable
to the study should be stated here explicitly. |
| |
|
|
| |
6) References: |
| |
In the text, references should
be cited with Arabic numerals in brackets and numbered in the order
cited. In the references section, the references should be numbered
in order of appearance in the text and listed in English. The total
number of references should be less than 25. List all authors if
there are less than or equal to six authors. List the first six
authors followed by "et al." if there are more than six
authors. If an article has been published online, but has not yet
been given an issue or pages, the digital object identifier (DOI)
should be supplied. Journal titles should be abbreviated in the
style used in Medline. Other types of references not described below
should follow Citing Medicine: The NLM Style Gui de for Authors,
Editors, and Publishers. |
| |
|
|
| |
Journal articles: |
| |
1. |
Baek KK, Lee J, Park SH, Park JO, Park YS, Lim HY,
et al. Oxaliplatin-induced chronic peripheral neurotoxicity: A prospective
analysis in patients with colorectal cancer. Cancer Res Treat. 2010;42:185-90. |
| |
2. |
Falcone A, Masi G, Loupakis F, Vasile E, Ciarlo A,
Cavaciocchi D, et al. FOLFOXIRI (irinotecan, oxaliplatin and infusional
5 FU/LV) in combination with bevacizumab in the first-line treatment
of metastatic colorectal cancer. J Clin Oncol. 2008;26 (15S):4031. |
| |
3. |
Zhang L, Jiang M, Zhou Y, Du XB, Yao WX, Yan X, et
al. Survey on breast cancer patients in China toward breast-conserving
surgery. Psycho-Oncology. 2011 Feb 14 [Epub]. Doi: 10.1002/pon.1922. |
| |
|
|
| |
Book: |
| |
4. |
Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB,
McKenna WG. Abeloff's clinical oncology. 4th ed. Philadelphia, PA:
Churchill Livingstone; 2008. |
| |
5. |
Wang JC, Dick JE. Cancer stem cells. In: DeVita VT,
Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg's
cancer: principles & practice of oncology. 8th ed. Philadelphia,
PA: Lippincott Willians & Wilkins; 2008. p. 135- 46 |
| |
|
|
| |
Conference
paper: |
| |
6. |
Cigler T, Singer O, Moore A, Chuang E, Vahdat LT,
Reichman VS, et al. Evaluation of vitamin D levels and aromatase
inhibitor-associated musculoskeletal symptoms. In: 2010 Breast Cancer
Symposium; 2010 Oct 1-3; Washington, DC. Columbia, MD: American
Society of Breast Surgeons; Abstr 166. |
| |
|
|
| |
Online
sources: |
| |
7. |
American Cancer Society. Cancer facts & figures [Internet].
Atlanta, GA: American Cancer Society; c2011 [cited 2011 Feb 20].
Available from: http://www.cancer.org/Research/CancerFactsFigures/index. |
| |
8. |
National Cancer Information Center. Cancer incidence
[Internet]. Goyang (KR): National Cancer Information Center; c2011
[cited 2010 Oct 20]. Available from: http://www.cancer.go.kr/cms/statics. |
| |
|
|
| |
7) Tables: |
| |
|
Tables should have a title, begin a new page, and
be numbered with Arabic numerals in the order in which they are
cited in the text. The title and contents of a table should be concise
and clear, so that a reader can understand the table without referring
to the text. The total number of tables should not exceed ten. Within
a table, if a non-standard abbreviation is used or description may
be necessary, then list them under annotation below. Use lowercase
letters in superscripts a), b), c) ... on the right side
of the part that needs explanation; the annotation should be recorded
according to the lowercase letters listed below the table. Statistical
measures such as SD or SE should be identified. Vertical or horizontal
lines between entries should be omitted. |
| |
|
|
| |
8) Figures: |
| |
|
Upload each figure as a separate image file. The figure
images should be provided in high resolution (preferably 300 dpi
for figures and 600 dpi for line art and graphs). They should be
submitted in EPS or TIF format, although JPEG format is allowed
for color figures. The figures should be sized to column width (8.5
cm or 17.5 cm). If the figures are not original, the author must
contact each publisher to request permission and this should be
remarked on in the footnote to the figure. Figures should be numbered,
using Arabic numerals, in the order in which they are cited. All
figures should be cited in the text (e.g., Fig. 1, Fig. 1A-C, Figs.
1 and 2). In the case of multiple prints bearing the same number,
use capital letters after the numerals to indicate the correct order
(e.g., Fig. 1A, Fig. 1B). The total number of figures must not exceed
ten. Figure legends should be in English and consist of a one-sentence
description rather than a phrase or a paragraph. A legend for each
light microscopic photograph should include the name of the stain
and magnification. Electron microscopic photographs should have
an internal scale marker. |
| |
|
|
REVIEWS / SPECIAL ARTICLES
Reviews are invited by the editor and should be comprehensive analyses of
specific topics. They are organized as follows: title page, abstract and
keywords, introduction, body text, conclusion, conflicts of interest,
acknowledgments, references, tables, and figure legends. Upload each
figure as a separate image file. There should be an unstructured abstract
equal to or less than 250 words. There is no specific requirement for
subsections of the body text of the paper.
EDITORIAL
Editorials are invited by the editors and should be commentaries on articles
published recently in the journal. Editorial topics could include active areas
of research, fresh insights, and debates. Editorials should be no more than
four to five pages in length including references, tables, and figures.
CASE REPORTS
Case reports will be published only in exceptional circumstances, when they
illustrate a rare occurrence of clinical importance. The manuscript for a case
report should be organized in the following sequence: title page, abstract
and keywords, introduction, case report(s), discussion, conflicts of interest,
acknowledgments (if necessary), references, tables, and figure legends.
Upload each figure as a separate image file. The abstract should be
unstructured and its length should not exceed 150 words. There should be
no more than five figures, including tables, and no more than 15 references.
6. COMMUNICATIONS TO THE PUBLISHER
We invite inquiries to the editorial office at any time during the editorial
process. For all matters concerning presubmission, editorial policies,
procedures, business inquiries, subscription information, orders, or changes
of address, please contact the editorial office.
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
163 Sinmunno 1-ga, Jongno-gu, Seoul 110-999, Korea
Tel.
Fax.
E-mail
7. ADDITIONAL INFORMATION
Copyright
All published papers become the permanent property of the Korean Cancer
Association. Upon acceptance of the manuscript, the authors will be
required to sign a statement confirming that the manuscript contains no
material the publication of which violates any copyright or other personal or
proprietary right of any person or entity.
Article Processing Charge
There is no submission fee or article processing charge since all cost
of publication is provided by the Korean Cancer Association.
Page Proofs
Corresponding authors are provided with page proofs and are asked to
carefully review them for data and typesetting errors. When proofs are
available, the corresponding author will receive a notification. Corrections to
proofs must be returned via mail or fax within 48 hours. Publication may be
delayed if proofs are not returned by the publisher's deadline.
Notice:
These recently revised instructions for authors will be applied beginning
with the March 2011 issue.
|
